Fig 5.

Dexmedetomidine elevated tumour retention in various organs, depending on the delivery method of tumour cells in two animal models. A) ECA inoculation in rats Dexmedetomidine (Dexmed) elevated MADB106 tumour retention in the brain, liver, lung, kidney, and muscle in the context of surgery, F344 female rats (n=13). Two-way ANOVA indicated a significant main effect of Dexmed (F_1,49 =28.861, p<0.0001) and a significant main effect of organ (F_4,49 =35.985, p<0.0001). B) Intravenous inoculation in rats Dexmed did not elevate MADB106 tumour retention in the brain, but did so in the lungs, kidneys and muscle, F344 female rats (n=9). Two-way ANOVA Indicated significant main effect for Dexmed (F_1,28 =21.905, p<0.0001) and for organ inspected (F_3,28 =18.334, p<0.0001). C) ECA inoculation in mice Male C57BL/6 mice (n=15) were injected with 3LL tumour cells via the ECA. Two-way ANOVA indicated significant main effect for Dexmed dose (F_{2, 132} =25.680, p<0.0001) and for organ (F_{4, 132} =60.122, p<0.0001).● indicates significant pair-wise difference from the organ-specific control (vehicle) group (PLSD, p < 0.05). Data presented as mean (SEM).